Sign In
Buy CDXC
$7.87
+0 (+0%)
At Close: Jun 17, 2025
ChromaDex Announces New Study Results Highlighting Promising Anti-Viral Effects of Niagen® in Coronavirus Cell Model
10:36am, Thursday, 09'th Jul 2020
ChromaDex Corp. (NASDAQ:CDXC) today announced the latest preclinical findings indicating Niagen® (patented nicotinamide riboside) inhibits replication of a form of Coronavirus, the virus that causes
ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a preclinical study in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National
ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a preclinical study in collaboration with the National Institute of Allergy and Infect
New Preclinical Findings Suggest Boosting NAD+ with Niagen® Holds Potential for Slowing Aging Process and Reducing Metabolic Damage
10:32am, Tuesday, 30'th Jun 2020
ChromaDex Corp. (NASDAQ:CDXC) today announced the results of multiple new preclinical studies that illustrate the multifaceted potential of Niagen® (nicotinamide riboside or NR) in bolstering cellula
New Preclinical Findings Suggest Boosting NAD+ with Niagen® Holds Potential for Slowing Aging Process and Reducing Metabolic Damage
12:00am, Tuesday, 30'th Jun 2020
ChromaDex Corp. (NASDAQ:CDXC) today announced the results of multiple new preclinical studies that illustrate the multifaceted potential of Niagen® (n
ChromaDex (CDXC) Presents At Lytham Partners Virtual Investor Growth Conference - Slideshow
01:38pm, Friday, 26'th Jun 2020
The following slide deck was published by ChromaDex Corporation in conjunction with this event.
Chromadex (NASDAQ:CDXC) Rating Increased to Buy at Zacks Investment Research
02:09am, Wednesday, 24'th Jun 2020
Chromadex (NASDAQ:CDXC) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Monday, Zacks.com reports. The firm currently has a $5.25 price
Zacks Investment Research Downgrades Chromadex (NASDAQ:CDXC) to Hold
02:18am, Sunday, 21'st Jun 2020
Chromadex (NASDAQ:CDXC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Friday, Zacks.com reports. According to Zacks, “Chroma
ChromaDex Research & Development Facility Earns ISO/IEC 17025:2017 Accreditation
10:33am, Wednesday, 17'th Jun 2020
ChromaDex Corp. (NASDAQ:CDXC) announced today it has achieved ISO/IEC 17025:2017 quality standard for laboratory testing, the world’s most respected quality management standard. This accreditation c
ChromaDex Research & Development Facility Earns ISO/IEC 17025:2017 Accreditation
12:00am, Wednesday, 17'th Jun 2020
ChromaDex Corp. (NASDAQ:CDXC) announced today it has achieved ISO/IEC 17025:2017 quality standard for laboratory testing, the world’s most respected q
Wolters Kluwer Hosts Lender-focused Webinar on COVID-19 Compliance-related Impacts | | IT Business Net
03:01pm, Tuesday, 16'th Jun 2020
June 18 Event Spotlights Paycheck Protection Program Loan Forgiveness, Other Regulatory Developments NEW YORK--(BUSINESS WIRE)--#cares--Wolters Kluwer Compliance Solutions is hosting an informational
ChromaDex to Present at June 2020 Lytham Partners Virtual Investor Growth Conference
10:32am, Tuesday, 16'th Jun 2020
ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 a
ChromaDex Corp. (NASDAQ:CDXC), a global scientific authority on nicotinamide adenine dinucleotide (NAD) and innovators behind Niagen® (patented nicotinamide riboside) science, announced today the pub
ChromaDex to Present at June 2020 Lytham Partners Virtual Investor Growth Conference
12:00am, Tuesday, 16'th Jun 2020
ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Invest
